Skip to content
Edarbi(azilsartan kamedoxomil)
Edarbi, Edarbyclor (azilsartan kamedoxomil) is a small molecule pharmaceutical. Azilsartan kamedoxomil was first approved as Edarbi on 2011-02-25. It is used to treat hypertension in the USA. It has been approved in Europe to treat hypertension.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Edarbi (generic drugs available since 2022-07-20)
Combinations
Edarbyclor
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Azilsartan kamedoxomil
Tradename
Company
Number
Date
Products
EDARBIAzurityN-200796 RX2011-02-25
2 products, RLD, RS
Azilsartan kamedoxomil
+
Chlorthalidone
Tradename
Company
Number
Date
Products
EDARBYCLORAzurityN-202331 RX2011-12-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
edarbiNew Drug Application2020-06-05
edarbyclorNew Drug Application2020-06-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Azilsartan Kamedoxomil / Chlorthalidone, Edarbyclor, Azurity
93872492031-07-01U-3
91692382030-02-04DP
Azilsartan Kamedoxomil, Edarbi, Azurity
90669362028-03-26DP
71575842025-05-22DP
75729202025-01-07DPU-3
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA09: Azilsartan medoxomil
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA09: Azilsartan medoxomil and diuretics
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HivD006678O98.711——12
Non-small-cell lung carcinomaD00228921———2
GlioblastomaD005909EFO_000051511———1
TuberculosisD014376EFO_0000774A15-A19—1———1
PainD010146EFO_0003843R52—1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Small cell lung carcinomaD05575211———1
Squamous cell neoplasmsD01830711———1
Adenocarcinoma of lungD00007719211———1
GiardiasisD005873DOID_10718A07.1—1———1
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801————1
AmebiasisD000562EFO_0007144A061————1
Fallopian tube neoplasmsD0051851————1
Ovarian epithelial carcinomaD0000772161————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAZILSARTAN KAMEDOXOMIL
INNazilsartan medoxomil
Description
Azilsartan is an angiotensin II receptor antagonist used in the treatment of hypertension, developed by Takeda. It is marketed in tablet form under the brand name Edarbi as the prodrug azilsartan medoxomil.
Classification
Small molecule
Drug classangiotensin II receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]
Identifiers
PDB—
CAS-ID147403-03-0
RxCUI1091643
ChEMBL IDCHEMBL2103795
ChEBI ID68847
PubChem CID9825285
DrugBankDB08822
UNII IDLL0G25K7I2 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 230 documents
View more details
Safety
Black-box Warning
Black-box warning for: Edarbi, Edarbyclor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
68 adverse events reported
View more details